Evidence map›Paper›PMID 42327793›Full record

ReviewFrontiers in immunology2026

Integrating

Haifang Chen, Zhiyu Chen, Mingna Sun, Lu Liang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Haifang Chen *Operations Management Department, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China.
Zhiyu Chen *Operations Management Department, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China.
Mingna SunOperations Management Department, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China.
Lu LiangOperations Management Department, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The traditional paradigm of linking single genes to individual phenotypes is being replaced by a systems-level framework to understand the complexity of the tumor microenvironment. In this context, in silico knockout has emerged as a powerful computational approach to predict system-wide responses to genetic or cellular perturbations. This review summarizes how multilayer regulatory information across the genome, transcriptome, proteome, and metabolome can be integrated into computational models for virtual perturbation analysis. We outline major multi-omics data sources, including bulk, single-cell, and spatial omics, and emphasize how these data are transformed into model-compatible inputs such as constraint-based matrices and latent embeddings. We then discuss the evolution of in silico knockout methodologies, from genome-scale metabolic models and flux balance analysis to advanced deep learning frameworks that enable the prediction of non-linear and unseen perturbations. The integration of spatial transcriptomics further extends these approaches to tissue-level modeling of cell-cell interactions. In tumor immunology, these methods facilitate the identification of immune regulatory genes, the analysis of immune evasion mechanisms, and the prioritization of therapeutic targets. Despite current challenges in multi-omics integration and biological complexity, in silico knockout provides a promising framework for advancing precision immunotherapy.

Indexed as

Gene Regulatory NetworksNeoplasmsPrecision MedicineAnimalsComputational BiologyComputer SimulationGenomicsHumansImmunoinformaticsMultiomicsTumor Microenvironmentfoundation modelsin silico knockoutmulti-omics integrationtumor immunologytumor microenvironment

Identifiers

PMID42327793
PMCPMC13279713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.